智通财经APP获悉，科济药业-B(02171)早盘涨超6%，截至发稿，涨5.43%，报16.3港元，成交额3212.85万港元。
消息面上，科济药业公布，舒瑞基奥仑赛注射液（研发代码：CT041）在中国开展的确证性II期临床试验研究结果摘要，已被2025年美国临床肿瘤学会(ASCO)年会接受进行口头报告。摘要和进一步信息将于美国东部时间今年5月22日后公布。据介绍，舒瑞基奥仑赛注射液用于治疗Claudin18.2阳性实体瘤，主要治疗胃癌/食管胃结合部腺癌及胰腺癌。
值得注意的是，科济药业近日宣布，其自主研发的舒瑞基奥仑赛注射液已被国家药品监督管理局药品审评中心纳入突破性治疗药物品种名单。科济药业预计将于2025年上半年向国家药品监督管理局递交该药物的新药上市申请。这一进展标志着CT041在临床治疗中的重要潜力，有望为晚期胃癌患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.